Immunotherapy trial targets recurrent brain tumors after chemotherapy
NCT ID NCT03557359
Summary
This study tested whether the immunotherapy drug nivolumab could help shrink recurrent brain tumors in adults who had previously received chemotherapy. The trial enrolled 35 adults with specific genetic mutations in their tumors that made them more likely to respond to immunotherapy. Researchers measured how many patients' tumors shrank and how long the treatment kept the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Miami Cancer Center
Miami, Florida, 33176, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.